Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 16;11(6):1656.
doi: 10.3390/jcm11061656.

New Generation Gepants: Migraine Acute and Preventive Medications

David Moreno-Ajona  1   2 , María Dolores Villar-Martínez  1   2 , Peter J Goadsby  1   2   3
Affiliations
Review

New Generation Gepants: Migraine Acute and Preventive Medications

David Moreno-Ajona et al. J Clin Med. .

Abstract

Migraine is a debilitating disease whose clinical and social impact is out of debate. Tolerability issues, interactions, contraindications, and inefficacy of the available medications make new options necessary. The calcitonin-gene-related peptide (CGRP) pathway has shown its importance in migraine pathophysiology and specific medications targeting this have become available. The first-generation CGRP receptor antagonists or gepants, have undergone clinical trials but their development was stopped because of hepatotoxicity. The new generation of gepants, however, are efficacious, safe, and well tolerated as per recent clinical trials. This led to the FDA-approval of rimegepant, ubrogepant, and atogepant. The clinical trials of the available gepants and some of the newer CGRP-antagonists are reviewed in this article.

Keywords: CGRP; acute medications; gepants; migraine; painkillers.

PubMed Disclaimer

Conflict of interest statement

D.M.-A. declares no conflict of interest. M.D.V.M. declares no conflict of interest. P.J.G. reports over the last 36 months, grants and personal fees from Amgen and Eli-Lilly and Company, grant from Celgene, and personal fees from Aeon Biopharma, Alder Biopharmaceuticals, Allergan, Autonomic Technologies Inc., Biohaven Pharmaceuticals Inc., Clexio, Electrocore LLC, eNeura, Epalex, Impel Neuropharma, MundiPharma, Novartis, Santara Therapeutics, Teva Pharmaceuticals, Trigemina Inc., WL Gore, and personal fees from MedicoLegal work, Massachusetts Medical Society, Up-to-Date, Oxford University Press, and Wolters Kluwer; and a patent magnetic stimulation for headache assigned to eNeura without fee.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211–1259. doi: 10.1016/S0140-6736(17)32154-2. - DOI - PMC - PubMed
    1. Bolay H., Gül A., Baykan B. COVID-19 is a Real Headache! Headache. 2020;60:1415–1421. doi: 10.1111/head.13856. - DOI - PMC - PubMed
    1. Halpin S., O’Connor R., Sivan M. Long COVID and chronic COVID syndromes. J. Med. Virol. 2021;93:1242–1243. doi: 10.1002/jmv.26587. - DOI - PMC - PubMed
    1. Venkatesan P. NICE guideline on long COVID. Lancet Respir. Med. 2021;9:129. doi: 10.1016/S2213-2600(21)00031-X. - DOI - PMC - PubMed
    1. Moreno-Ajona D., Villar-Martínez M.D., Goadsby P.J. Targets for migraine treatment: Beyond calcitonin gene-related peptide. Curr. Opin. Neurol. 2021;34:363–372. doi: 10.1097/WCO.0000000000000935. - DOI - PubMed